

From: [REDACTED] (Swansea Bay UHB - Ophthalmology)

<[REDACTED]>

Sent: Tuesday, May 20, 2025 8:30 am

To: [REDACTED]

[REDACTED]

Subject: FW: 1. Urgent Medicine Supply Information - Kenalog usage in Ophthalmology

Dear All

Please see attached – sent on behalf of Mr G N Shuttleworth.

Kind regards

[REDACTED]

[REDACTED]

From: [REDACTED]

Sent: Monday, May 19, 2025 6:04:21 PM

To: [REDACTED]

Subject: 1. Urgent Medicine Supply Information - Kenalog usage in Ophthalmology

You don't often get email from [REDACTED]. [Learn why this is important](#)

WARNING: This email originated from outside of NHS Wales. Do not open links or attachments unless you know the content is safe.

Dear Clinical, Medical & Pharmacy Team,

This communication addresses the recent notification from NHS England (2) regarding the discontinuation of Adcortyl® and Kenalog® injections. Please find enclosed comprehensive product information for Intracinol®(1).

Given the critical need for a suitable alternative in ophthalmological practice, we strongly recommend the immediate consideration of Intracinol® (triamcinolone acetonide) as the preferred replacement for Kenalog® 40mg/ml injection. Intracinol® is specifically manufactured and formulated for intraocular administration, adhering to stringent sterility and particulate matter standards essential for maintaining ocular safety. The use of a product designed for ophthalmic application is paramount in minimising potential risks associated with formulations intended for non-ocular routes.

Furthermore, Intracinol® offers a readily accessible solution through direct ordering from Alloga with next-day delivery. This streamlined procurement process avoids the complexities and potential delays inherent in sourcing unlicensed 'specials', ensuring uninterrupted patient access to necessary treatment.

While acknowledging the information regarding alternative systemic steroid preparations, it is crucial to recognise that these may not always provide the direct and localised action frequently required in ophthalmology. Intracinol® presents a familiar therapeutic agent in a formulation specifically tailored for intraocular use, thereby enabling ophthalmologists to maintain established treatment protocols with confidence and without delay. It's crucial to note that any imported versions of Kenalog will also be subject to the same restrictions detailed in its Summary of Product Characteristics (SPC)(1).

To ensure a smooth and safe transition for patients requiring intraocular triamcinolone, it is crucial that this information is promptly shared with all relevant clinicians, pharmacy teams, and management personnel.

Action Required:

- **Clinical Ophthalmologists:** Review this guidance and consider Intracinol® as the primary alternative to Kenalog® 40mg/ml injection. Assess the need for Intracinol® formulary inclusion or a listing amendment.
- **For Awareness:** Please forward this information to the Lead Nurse in Theatres.
- **Pharmacy Teams:** Update all relevant formularies with new options as per the enclosed NHS England guidance.
-
- **Management Personnel:** Ensure that formulary updates are implemented effectively and communicated across the appropriate teams.
- **Pharmacist Responsible for Formulary Updates:** Please review and action the enclosed guidance without delay.

Kenalog is commonly listed on formularies for ophthalmic use. It is imperative that these formularies are updated accordingly and that Intracinol® is considered as the preferred replacement to ensure continuity of care.

Please take immediate action and confirm that the necessary updates have been made.

Kind regards

A large black rectangular redaction box covering the signature and name of the sender.

PRIVILEGED AND CONFIDENTIAL COMMUNICATION This e-mail transmission, and any documents, files or previous e-mail messages attached to it, may contain confidential information that is legally privileged. If you are not the intended recipient or a person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of any of the information contained in or attached to this transmission is **STRICTLY PROHIBITED**. If you have received this transmission in error, please: (1) immediately notify me by reply e-mail, or by collect telephone call; and (2) destroy the original transmission and its attachments without reading or saving in any manner.